Log In
Print
BCIQ
Print
Print this Print this
 

LixiLan, Lixisenatide/ZP10+Lantus

  Manage Alerts
Collapse Summary General Information
Company Zealand Pharma A/S
DescriptionCombination of Lyxumia lixisenatide/ZP10 and Lantus insulin glargine
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase III
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner

Sanofi


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today